The estimated Net Worth of Kenneth Cunningham is at least $2.03 Million dollars as of 4 May 2021. Kenneth Cunningham owns over 13,112 units of Verona Pharma Plc stock worth over $2,007,508 and over the last 4 years Kenneth sold VRNA stock worth over $23,987.
Kenneth has made over 2 trades of the Verona Pharma Plc stock since 2021, according to the Form 4 filled with the SEC. Most recently Kenneth sold 13,112 units of VRNA stock worth $11,014 on 4 May 2021.
The largest trade Kenneth's ever made was selling 13,112 units of Verona Pharma Plc stock on 4 May 2021 worth over $11,014. On average, Kenneth trades about 4,369 units every 15 days since 2021. As of 4 May 2021 Kenneth still owns at least 66,584 units of Verona Pharma Plc stock.
You can see the complete history of Kenneth Cunningham stock trades at the bottom of the page.
Kenneth's mailing address filed with the SEC is 3 MORE LONDON RIVERSIDE, , LONDON, X0, SE1 2RE.
Over the last 4 years, insiders at Verona Pharma Plc have traded over $308,854,297 worth of Verona Pharma Plc stock and bought 5,029,736 units worth $6,770,194 . The most active insiders traders include Andrew Sinclair, Advisors Llc Orbi Med Capit... und Rishi Gupta. On average, Verona Pharma Plc executives and independent directors trade stock every 18 days with the average trade being worth of $11,234,071. The most recent stock trade was executed by David Zaccardelli on 12 August 2024, trading 400,000 units of VRNA stock currently worth $1,280,000.
verona pharma is a clinical stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. we are currently focused on developing our novel lead therapeutic candidate in the treatment of chronic obstructive pulmonary fibrosis (copd) and cystic fibrosis (cf), and may expand our pipeline to help address the gaps in treatment of other respiratory diseases. we are led by a team with deep industry experience, including extensive backgrounds in the discovery, development and commercialization of respiratory therapies. in addition, we have established relationships with leading research institutions and advocacy organizations in the respiratory space and have received awards in support of our continued work and innovation. verona pharma is listed on the nasdaq global market in the united states under the ticker symbol vrna and on the london stock exchange in the united kin
Verona Pharma Plc executives and other stock owners filed with the SEC include: